Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | FLT1 | P17948 | 3/20 | 0.44 |
| ▸ | FLT4 | P35916 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381364 | 0.88 | GPR119 (0.48) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10120672 | 0.86 | GPR119 (0.47) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10105782 | 0.85 | GPR119 (0.50) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10120557 | 0.85 | GPR119 (0.51) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL15381343 | 0.82 | GPR119 (0.54) | GPR119 | |
| SCHEMBL10120507 | 0.79 | GPR119 (0.51) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10120559 | 0.79 | GPR119 (0.51) | GPR119 | |
| SCHEMBL10120519 | 0.78 | GPR119 (0.58) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10134277 | 0.77 | GPR119 (0.49) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10120569 | 0.77 | EIF4E (0.51) | GPR119FGFR1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885FGFR1 131/4885FLT1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.